Nanogen to Release Preliminary Fourth Quarter Financial Results and Host Webcast on Thursday, February 23, 2006

Feb 21, 2006, 00:00 ET from Nanogen, Inc.

    SAN DIEGO, Feb. 21 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq:   NGEN)
 will host a conference call on Thursday, February 23, 2006 at 4:30 p.m.
 Eastern (1:30 p.m. Pacific) to discuss preliminary 2005 fourth quarter and
 year-end financial results.  The financial results press release will be
 issued at close of market on February 23rd.  Interested investors and others
 may participate in the conference call by dialing 877-407-9210 for US/Canada
 participants, and 201-689-8049 for international participants.
     Audio of management's presentation will also be available via live webcast
 on the investor relations section of Nanogen's corporate website at, and will be archived for 90 days.  A digital recording of the
 call will also be available for 48 hours, beginning two hours after the
 completion of the conference call on February 23, and can be accessed via
 telephone at 877-660-6853 for US/Canada callers, and 201-612-7415 for
 international callers.  The account number, 286, along with the conference
 ID, 194025, will be required to listen to the playback.
     About Nanogen, Inc.
     Nanogen's advanced technologies provide researchers, clinicians and
 physicians worldwide with improved methods and tools to predict, diagnose, and
 ultimately help treat disease.  The company's products include real-time PCR
 reagents, the NanoChip(R) electronic microarray platform and a line of rapid,
 point-of-care diagnostic tests.  Nanogen's ten years of pioneering research
 involving nanotechnology holds the promise of miniaturization and continues to
 be supported for its potential for diagnostic and biowarfare applications.
 For additional information please visit Nanogen's website at
     Forward-Looking Statement
     This press release contains forward-looking statements that are subject to
 risks and uncertainties that could cause actual results to differ materially
 from those set forth in the forward-looking statements, including whether
 patents owned or licensed by Nanogen will be developed into products, whether
 the patents owned by Nanogen offer any protection against competitors with
 competing technologies, whether products under development can be successfully
 developed and commercialized, whether results reported by our customers or
 partners can be identically replicated, and other risks and uncertainties
 discussed under the caption "Factors That May Affect Results" and elsewhere in
 Nanogen's Form 10-K or Form 10-Q most recently filed with the Securities and
 Exchange Commission.  These forward-looking statements speak only as of the
 date hereof.  Nanogen disclaims any intent or obligation to update these
 forward-looking statements.

SOURCE Nanogen, Inc.